Vispa-cel (CB-010)

May 12, 2026 — Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that two abstracts were accepted for oral presentation at the 2026 European Hematology Association (EHA) Annual Meeting (June 11–14, 2026; Stockholm). One presentation will report long-term durability after a single dose of vispacabtagene regedleucel (vispa-cel; CB-010), an allogeneic anti-CD19 CAR‑T with PD‑1 knockout, from the ANTLER phase 1 trial in relapsed/refractory B‑cell non-Hodgkin lymphoma. As of the Sept 2, 2025 data cutoff, 84 patients were treated; 80×10^6 CAR‑T cells was selected as the recommended phase 2 dose, and 63 second-line LBCL patients were treated in dose expansion.

A second presentation will provide longer follow-up from dose escalation in the CaMMouflage phase 1 trial of CB‑011, an allogeneic anti‑BCMA CAR‑T using an immune-cloaking strategy (B2M knockout plus B2M–HLA‑E fusion) in relapsed/refractory multiple myeloma. Dose escalation evaluated 48 patients across multiple doses and two lymphodepletion regimens; dose expansion is using 450×10^6 cells with cyclophosphamide 500 mg/m^2 and fludarabine 30 mg/m^2 for 3 days. Both programs have FDA RMAT, Fast Track, and Orphan Drug designations, supporting their regulatory and commercial potential.